Mid-term outcomes of orbital atherectomy combined with drug-coated balloon angioplasty for treatment of femoropopliteal disease

Catheterization and Cardiovascular Interventions

Volumn 89, Issue 6, 2017, Pages 1078-1085

  Foley, T Raymond ^a   Cotter, Ryan P ^a   Kokkinidis, Damianos G ^a   Nguyen, Daniel D ^a   Waldo, Stephen W ^a   Armstrong, Ehrin J ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

calcification; peripheral artery disease; peripheral intervention; superficial femoral artery

Indexed keywords

AGED; ARTICLE; ATHERECTOMY; CALCIFICATION; CLAUDICATION; COHORT ANALYSIS; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; DRUG COATED BALLOON ANGIOPLASTY; FEMALE; HEMATOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; ORBITAL ATHERECTOMY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; TARGET LESION REVASCULARIZATION; TREATMENT OUTCOME; ANGIOGRAPHY; BLOOD VESSEL CALCIFICATION; COLORADO; CRITICAL ILLNESS; DEVICES; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; EQUIPMENT DESIGN; FEMORAL ARTERY; INTERMITTENT CLAUDICATION; ISCHEMIA; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; VASCULAR ACCESS DEVICE; VASCULAR PATENCY;

BIOCOMPATIBLE COATED MATERIAL;

AGED; ANGIOGRAPHY; ANGIOPLASTY, BALLOON; ATHERECTOMY; COATED MATERIALS, BIOCOMPATIBLE; COLORADO; CRITICAL ILLNESS; DISEASE-FREE SURVIVAL; EQUIPMENT DESIGN; FEMALE; FEMORAL ARTERY; HUMANS; INTERMITTENT CLAUDICATION; ISCHEMIA; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ACCESS DEVICES; VASCULAR CALCIFICATION; VASCULAR PATENCY;

EID: 85015177473     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.26984     Document Type: Article

References (30)

1. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation 2006;113:e463–e465. doi:10.1161/CIRCULATIONAHA.106.174526.
2. Endorsed by: the European Stroke Organisation (ESO), Authors/Task Force Members, Tendera M. et al. ESC guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2851–2906. doi:10.1093/eurheartj/ehr211.
3. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR. Intersociety consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007;33:S1–S75. doi:10.1016/j.ejvs.2006.09.024.
4. Schlager O, Dick P, Sabeti S, et al. Long-segment SFA stenting—The dark sides: In-stent restenosis, clinical deterioration, and stent fractures. J Endovasc Ther 2005;12:676–684. doi:10.1583/05-1672.1.
5. Thukkani AK, Kinlay S. Endovascular intervention for peripheral artery disease. Circ Res 2015;116:1599–1613. doi:10.1161/CIRCRESAHA.116.303503.
6. Tepe G, Schnorr B, Albrecht T, et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons. JACC Cardiovasc Interv 2015;8:102–108. doi:10.1016/j.jcin.2014.07.023.
7. Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization. JACC Cardiovasc Interv 2014;7:10–19. doi:10.1016/j.jcin.2013.05.022.
8. Micari A, Cioppa A, Vadalà G, et al. Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease. JACC Cardiovasc Interv 2012;5:331–338. doi:10.1016/j.jcin.2011.11.010.
9. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008;358:689–699. doi:10.1056/NEJMoa0706356.
10. Tepe G, Beschorner U, Ruether C, et al. Drug-eluting balloon therapy for femoropopliteal occlusive disease: Predictors of outcome with a special emphasis on calcium. J Endovasc Ther 2015;22:727–733. doi:10.1177/1526602815600156.
11. Atherectomy Followed by a Drug Coated Balloon to Treat Peripheral Arterial Disease - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01366482. Accessed December 11, 2016.
12. Shammas NW, Lam R, Mustapha J, et al. Comparison of orbital atherectomy plus balloon angioplasty vs. balloon angioplasty alone in patients with critical limb ischemia: Results of the CALCIUM 360 randomized pilot trial. J Endovasc Ther 2012;19:480–488. doi:10.1583/JEVT-12-3815MR.1.
13. Cioppa A, Stabile E, Popusoi G, et al. Combined treatment of heavy calcified femoro-popliteal lesions using directional atherectomy and a paclitaxel coated balloon: One-year single centre clinical results. Cardiovasc Revasc Med 2012;13:219–223. doi:10.1016/j.carrev.2012.04.007.
14. Fanelli F, Cannavale A, Gazzetti M, et al. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol 2014;37:898–907. doi:10.1007/s00270-014-0904-3.
15. Dattilo R, Himmelstein SI, Cuff RF. The COMPLIANCE 360° trial: A randomized, prospective, multicenter, pilot study comparing acute and long-term results of orbital atherectomy to balloon angioplasty for calcified femoropopliteal disease. J Invasive Cardiol 2014;26:355–360.
16. Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation 2015;131:495–502. doi:10.1161/CIRCULATIONAHA.114.011004.
17. Scheinert D, Katsanos K, Zeller T, et al. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease. J Am Coll Cardiol 2012;60:2290–2295. doi:10.1016/j.jacc.2012.08.989.
18. Laird JR, Schneider PA, Tepe G, et al. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions. J Am Coll Cardiol 2015;66:2329–2338. doi:10.1016/j.jacc.2015.09.063.
19. Liistro F, Grotti S, Porto I, et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery. JACC Cardiovasc Interv 2013;6:1295–1302. doi:10.1016/j.jcin.2013.07.010.
20. Micari A, Vadalà G, Castriota F, et al. 1-year results of paclitaxel-coated balloons for long femoropopliteal artery disease. JACC Cardiovasc Interv 2016;9:950–956. doi:10.1016/j.jcin.2016.02.014.
21. Armstrong EJ, Saeed H, Alvandi B, et al. Nitinol self-expanding stents vs. balloon angioplasty for very long femoropopliteal lesions. J Endovasc Ther 2014;21:34–43. doi:10.1583/13-4399MR.1.
22. ® single arm study: 12-month results from the TASC C/D lesion subgroup. J Cardiovasc Surg (Torino) 2013;54:115–122.
23. Zeller T, Peeters P, Bosiers M, et al. Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: The Viabahn-25 cm trial. J Endovasc Ther 2014;21:765–774. doi:10.1583/14-4790R.1.
24. Axel DI, Kunert W, Göggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636–645.
25. Oberhoff M, Kunert W, Herdeg C, et al. Inhibition of smooth muscle cell proliferation after local drug delivery of the antimitotic drug paclitaxel using a porous balloon catheter. Basic Res Cardiol 2001;96:275–282.
26. Hawkins BM, Hennebry TA. Local paclitaxel delivery for treatment of peripheral arterial disease. Circ Cardiovasc Interv 2011;4:297–302. doi:10.1161/CIRCINTERVENTIONS.110.961052.
27. Feldman DN. Atherectomy for calcified femoropopliteal disease: Are we making progress? J Invasive Cardiol 2014;26:304–306.
28. Adams GL, Das T, Lee MS, Beasley R, Mustapha J. Subanalysis of the CONFIRM registries: Acute procedural outcomes in claudicant and critical limb ischemia patients with varying levels of calcification treated for peripheral arterial disease with orbital atherectomy. J Invasive Cardiol 2015;27:516–520.
29. Atherectomy Followed by a Drug Coated Balloon to Treat Peripheral Arterial Disease - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01366482. Accessed June 3, 2016.
30. Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 2005;45:312–315. doi:10.1016/j.jacc.2004.11.026.